Randomized controlled trialHumanClinical Trial, Phase I
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
Muscle & nerve, 2013 Mar. Attie KM, Borgstein NG, Yang Y and 7 others.
Study type
Randomized controlled trial · Clinical Trial, Phase I
Subjects
Human participants (PubMed MeSH: Humans)
Journal
Muscle & nerve
Published
2013 Mar
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
Absorptiometry, PhotonActivin Receptors, Type IIAdipose TissueAgedBiomarkersBody CompositionBone DensityCohort StudiesDose-Response Relationship, DrugDouble-Blind MethodEndpoint DeterminationFemale
Other papers on ACE-031
Randomized controlled trial · 2026
Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults
Randomized controlled trial · 2017Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page